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Abstract
Background: The objective of this study was to evaluate the efficacy and toxicity of infusional 5-
fluorouracil (5-FU), folinic acid and oxaliplatin (modified FOLFOX-6) in patients with advanced
gastric cancer (AGC), as first-line palliative combination chemotherapy. We also analyzed the
predictive or prognostic value of germline polymorphisms of candidate genes associated with 5-FU
and oxaliplatin.
Methods: Seventy-three patients were administered a 2 hour infusion of oxaliplatin (100 mg/m2)
and folinic acid (100 mg/m2) followed by a 46 hour continuous infusion of 5-FU (2,400 mg/m2).
Genomic DNA from the patients' peripheral blood mononuclear cells was extracted. Ten
polymorphisms within five genes were investigated including TS, GSTP, ERCC, XPD and XRCC.
Results: The overall response rate (RR) was 43.8%. Median time to progression (TTP) and overall
survival (OS) were 6.0 months and 12.6 months, respectively. Toxicities were generally tolerable
and manageable. The RR was significantly higher in patients with a 6-bp deletion homozygote (-6
bp/-6 bp) in TS-3'UTR (55.0% vs. 30.3% in +6 bp/+6 bp or +6 bp/-6 bp, p = 0.034), and C/A or A/
A in XPD156 (52.0% vs. 26.1% in C/C, p = 0.038). The -6 bp/-6 bp in TS-3'UTR was significantly
associated with a prolonged TTP and OS. In a multivariate analysis, the 6-bp deletion in TS-3'UTR
was identified as an independent prognostic marker of TTP (hazard ratio = 0.561, p = 0.032).
Conclusion: Modified FOLFOX-6 chemotherapy appears to be active and well tolerated as first
line chemotherapy in AGC patients. The 6-bp deletion in TS-3'UTR might be a candidate to select
patients who are likely to benefit from 5-FU based modified FOLFOX-6 in future large scale trial.
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Background
Despite improvements in the early detection of gastric
cancer, a significant proportion of patients present with
inoperable stages where chemotherapy is required. 5-
fluorouracil (5-FU) remains the main chemotherapeutic
agent for the treatment of gastric cancer, and combination
chemotherapy with 5-FU has shown an improved clinical
outcomes [1]. 5-FU with cisplatin showed an effective
clinical outcome [2], however, toxicities were considera-
ble [1]. Oxaliplatin, another platinum based agent, has a
more favorable tolerability profile than cisplatin. Hence, a
combination chemotherapy of 5-FU with oxaliplatin has
been investigated in numerous phase II studies, using dif-
ferent doses and schedules [3-7]. However it remains to be
clarified which is the best combination, with the highest
efficacy and lowest toxicity. Thus, we conducted a phase II
trial of 5-FU, folinic acid and oxaliplatin (a modified FOL-
FOX-6 regimen) in advanced gastric cancer (AGC)
patients as a first line palliative chemotherapy.
Another problem in chemotherapy of AGC is the selection
of patients who might benefit from specific chemother-
apy. One promising therapeutic challenge is to identify
genetic markers based on pharmacogenomics. Genomic
polymorphism can influence drug transport, metabolism
and cellular response, and lead to individual variations in
terms of the response and toxicity and even to overall sur-
vival [8,9]. A number of studies have investigated the rela-
tionships between treatment outcomes and individual
genetic polymorphisms which will determine the effica-
cies and toxicities of chemotherapeutic agents, especially
of 5-FU and platinum agents.
The antitumor effect of 5-FU has ascribed to the competi-
tive inhibition of thymidylate synthase (TS) [10]. A high
intratumoral TS expression has been correlated with
resistance to 5-FU and a poor clinical outcome in colorec-
tal cancer [11-14]. Several polymorphisms in TS may
influence TS mRNA transcription, stability, or protein
expression. Polymorphisms with double or triple repeats
of a 28-base pair (bp) sequence in the enhancer region
(ER) are known to be associated with the efficacy and tox-
icity of 5-FU [15-17]. The -6 bp/-6 bp deletion polymor-
phism in the 3'UTR of TS is associated with decreased
mRNA stability in vitro and lower intratumoral TS expres-
sion in vivo. Further, the 6 bp polymorphism varies greatly
within different ethnic populations and is in linkage dise-
quilibrium with the TS 5' tandem repeat enhancer poly-
morphism [18]. A functional G/C single nucleotide
polymorphism (SNP) within a second repeat of triple
repeat (3R) allele was found to determine two additional
alleles (3G or 3C) at this locus [19]. In vitro, the 3G con-
taining genotype showed a higher TS mRNA expression
[19,20].
Oxaliplatin has antitumor activity by virtue of its ability to
form platinum-DNA adducts. Bulky platinum-DNA
adducts are mainly repaired by the nucleotide excision
repair pathway, in which proteins of the excision repair
cross-complementation 1 (ERCC1), xeroderma pigmen-
tosum group D (XPD, also known as ERCC2) and X-ray
repair cross-complementing group (XRCC), have impor-
tant roles [13,21]. ERCC, XPD and XRCC contain SNPs
that may confer different activities to platinum agents,
thus modifying the clinical outcome [22-24]. Glutathione
S- transferase π 1 (GSTP1), which is involved in platinum
detoxification, also has a polymorphism that is associated
with prolonged survival in cisplatin-treated gastric cancer
[25,26].
The primary endpoint of this study was to evaluate the
efficacy in terms of response rate and the secondary end-
points of this study were to evaluate the efficacy in terms
of time to progression, overall survival and toxicity of
modified FOLFOX-6 chemotherapy in AGC patients.
Exploratory pharmacogenomic collateral study was per-
formed to identify the predictive or prognostic value of
germline polymorphisms of candidate genes associated
with 5-FU and oxaliplatin.
Methods
Patients
Patients with metastatic or relapsed AGC were enrolled in
this prospective phase II clinical trial. Patients were
administered a modified FOLFOX-6 regimen composed
of a 2 hours infusion of oxaliplatin (100 mg/m2) and foli-
nic acid (100 mg/m2), followed by a 46 hour continuous
infusion of 5-FU (2,400 mg/m2), as a first-line palliative
chemotherapy. Treatment was repeated every 2 weeks
until disease progression, patient refusal or unacceptable
adverse reactions.
Eligibility criteria included: 1) pathologically confirmed
gastric adenocarcinoma with a bi-dimensionally measur-
able lesion; 2) no prior chemotherapy except adjuvant
chemotherapy administered more than 6 months previ-
ously; 3) ECOG performance 0–2; 4) adequate bone mar-
row, hepatic, and renal functions. ECOG performance
status [27] defined as follows: ECOG 0-fully active, able to
carry on all pre-disease performance without restriction;
ECOG 1-restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or seden-
tary nature; ECOG 2 – ambulatory and capable of all self
care but unable to carry out any work activities; ECOG3 –
capable of only limited self care, confined to bed or chair
more than 50% of waking hours; ECOG 4 – completely
disabled.
Patients received a blood test for toxicity every cycle and
were re-evaluated every 3 cycles by abdominal computedBMC Cancer 2008, 8:148 http://www.biomedcentral.com/1471-2407/8/148
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tomography. The tumor responses were evaluated using
WHO criteria [28] and all responses were confirmed at
least 4 weeks after initial assessment. Toxicity was graded
according to National Cancer Institute common terminol-
ogy criteria for adverse events (CTCAE version 3.0).
Peripheral sensory neuropathy was also graded according
to same toxicity criteria. In the event of toxicity, dose mod-
ification and treatment delays were performed according
to the protocol. Dose modification of oxaliplatin to 85
mg/m2 was planned if the patient experienced grade 2 or
3 sensory neuropathy and we strictly followed the proto-
col which permitted the initiation of chemotherapy after
recovery from all toxicities less than grade 2.
Genotyping
To evaluate the clinical usefulness of germline genotyp-
ing, we analyzed peripheral blood samples that were
obtained from patients with informed consent. Genomic
DNA was extracted from peripheral blood samples using
QIAmp DNA blood kits (Qiagen Inc, Valencia, CA, USA),
and each polymorphism was analyzed using polymerase
chain reaction-restriction fragment length polymorphism
methods. Table 1 summarizes the primer sequences, the
restriction enzymes used [15,16,19,29-34]. The polymor-
phisms investigated included TS (28-bp repeat in
enhancer region [16], G/C SNP in the 3R allele [19], a 6-
bp deletion in 3'UTR [15]), GSTP1 (Ile105Val [29]),
ERCC1 (Asn118Asn [30], C8092A [31]), XPD (Arg156Arg
[32], Asp312Asn [33], Lys751Gln [33]), and XRCC
(Arg399Gln [34]).
The study protocol was reviewed and approved by the
institutional review board of Seoul National University
Hospital.
Statistical analyses
A single-stage design by A'Hern is chosen for definition of
the total number of patients required for the phase II
study [35]. We set response rate of 35% as the target activ-
ity level [6] and chose 20% as the lowest response rate.
Our study is designed to have 90% power to accept the
hypothesis and 5% significance to reject the hypothesis.
In this phase II study, at least 73 evaluable patients will be
required to be enrolled. Associations between response
rate and polymorphism were assessed by a Chi-square test
and Fisher's exact test, where appropriate. To verify allelic
frequencies, a Chi-square test was used to confirm agree-
ment with the Hardy-Weinberg equilibrium. Time to pro-
Table 1: Primer sequences and restriction enzymes
Gene Polymorphisms Location Primer Restriction 
enzyme
References
TS (Ch 18p11.32) 2R or 3R VNTR in ER* ER (5'UTR) Forward: GTGGCTCCTGCGTTTCCCCC 16
Backward: 
GCTCCGAGCCGGCCACAGGCATGGCGCGG
G/C SNP in 3R 5'UTR Forward:: GTGGCTCCTGCGTTTCCCCC Hae III 19
Backward: 
GCTCCGAGCCGGCCACAGGCATGGCGCGG
6 bp insertion(+)/
deletion(-)
3'UTR Forward: CAAATCTGAGGGAGCTGAGT Dra I 15
Backward: CAGATAAGTGGCAGTACAGA
GSTP1 (Ch.11q13) A/G, Ile105Val Exon5 Forward: CTCTATGGGAAGGACCAGCA BsmA I 29
Backward: TGAGGGCACAAGAAGCCCCT
ERCC1 (Ch.19q13.2) C/T, Asn118Asn Exon4 Forward: TCATCCCTATTGATGGCTTCTGCCC BsrD I 30
Backward: GACCATGCCCAGAGGCTTCTCATAG
C8092A 3'UTR Forward: CAGAGACAGTGCCCCAAGAG Mbo II 31
Backward: GGGCACCTTCAGCTTTCTTT
XPD (Ch.19q13.3) C/A, Arg156Arg Exon6 Forward: CACACCTGGCTCATTTTTGTAT Tfi I 32
Backward: TCATCCAGGTTGTAGATGCCA
G/A, Asp312Asn Exon10 Forward: 
CTGTTGGTGGGTGCCCGTATCTGTTGGTCT
Sty I 33
Backward: 
(TAATA)TCGGGGCTCACCCTGCAGCACTTCCT
A/C, Lys751Gln Exon23 Forward: GCCCGCTCTGGATTATACG Pst I 33
Backward: CTATCATCTCCTGGCCCCC
XRCC (Ch.19q13.2) G/A, Arg399Gln Exon10 Forward: TTGTGCTTTCTCTGTGTCCA Msp I 34
Backward: TCCTCCAGCCTTTTCTGATA
Ch, chromosome; VNTR, variable number tandem repeats; UTR, untranslated region; ER, enhancer region; TS, thymidylate synthase; GSTP, 
glutathione S- transferase π; ERCC1, excision repair cross-complementation 1; XPD, xeroderma pigmentosum group D; XRCC, X-ray repair cross-
complementing group.
*VNTR polymorphism is a double repeat (2R) or triple repeat (3R) of 28-bp sequence in TS 5'UTR.BMC Cancer 2008, 8:148 http://www.biomedcentral.com/1471-2407/8/148
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gression (TTP) was defined as the interval between the
initiation of treatment and the date when disease progres-
sion was first documented, or the date of death from any
cause. Overall survival (OS) was measured from the date
of treatment initiation to the date of death. Median TTP
and OS according to prognostic factors were calculated
using the Kaplan-Meier method. Multivariate analyses
were carried out using Cox proportional hazard regression
models for TTP and OS. All values were two sided and sta-
tistical significance was accepted at the p < 0.05 level. SPSS
version 12.0 software (SPSS, Inc., Chicago, IL, USA) was
used for all statistical analyses.
Cell culture and 5-FU sensitivity
Seven human gastric cancer cell lines (SNU 1, 5, 16, 484,
601, 620 and 638, obtained from the Korean Cell Line
Bank, Seoul, Korea) were examined. Genotypes of each
cell line were determined by same methods as described
above. Equal numbers of cells harvested during the expo-
nential growth phase were plated in 100 μl per well with
various concentrations (0.1 nM to 50 μM, diluted in sem-
ilog fashion) for 72 hours. The growth inhibition was
assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide test (MTT test; Sigma, St
Louis, MO, USA) and the concentrations required to
inhibit cell growth by 50% (IC50) were calculated.
Western blot
TS protein expressions were determined by Western
immunoblotting, as previously described [36]. Equivalent
amounts of protein were processed by 12% SDS-PAGE,
and electroblotted on to Hybond ECL nitrocellulose
membranes, which were blocked overnight using block-
ing buffer, and then incubated with primary antibody
against human TS (monoclonal mouse anti-TS antibody
1:1000 dilution in blocking buffer; TS Ab-1, clone TS106,
Neomarkers). Proteins were detected by enhanced chemi-
luminescence. For the semiquantitative analysis of West-
ern blots, subsaturated autoradiograms were scanned and
signals were analyzed by densitometry (TINA 2.09 soft-
ware; Raytest, Straubenhardt, Germany).
Results
Patient characteristics and clinical outcomes
Eighty patients were included in this trial and 7 patients
were lost to follow up. A total of 73 patients, composed of
48 men and 25 women, with a median age of 59 years
(range: 24–77) were finally evaluated in the study which
ran from March 2003 to March 2005. The clinical charac-
teristics of patients are summarized in Table 2. During a
median follow-up of 21.2 months, 42 death events and 68
progression events occurred. A total of 470 cycles of mod-
ified FOLFOX-6 were delivered with a median number of
6 cycles per patient (range, one to 12). Dose intensity level
was 83.2%. The median cumulative dose for oxaliplatin
was 570 mg/m2. The overall response rate (RR) was 43.8%
(Table 3). The median TTP and OS were 6.0 months (95%
CI, 4.8–7.2 months) and 12.6 months (95% CI, 8.7–16.5
months), respectively. Only performance status was
found to be a statistically significant prognostic factor for
TTP (6.3 months in ECOG 0–1 vs. 3.7 months in ECOG 2,
p = 0.037). RR, TTP and OS were not different according
to histotype (diffuse vs. intestinal type). Otherwise no sig-
nificant association was observed between patient charac-
teristics and clinical outcomes.
Toxicities
Severe hematologic toxicities were uncommon (Table 4).
The main grade 3 and 4 toxicity (per patients) was neutro-
penia (11.0%). Non-hematologic toxicities were mild and
1.4% experienced grade 3 peripheral neuropathy. No
febrile neutropenia was observed. Toxicities were gener-
ally brief, reversible and manageable.
Correlation between genotypes and response rates
We analyzed 10 germline polymorphisms within 5 genes.
All observed genotype frequencies were in agreement with
the Hardy-Weinberg equilibrium. The genotype distribu-
tions of -6 bp/-6 bp, +6 bp/-6 bp and +6 bp/+6 bp were
observed in 40 (54.8%), 30 (41.1%) and 3 (4.1%),
respectively. The frequencies of 3G containing genotype
and non-3G containing genotype were 69.9% and 28.8%,
respectively. Table 5 compares RR and polymorphisms.
RR was significantly higher in patients with a -6 bp/-6 bp
homozygote in TS-3'UTR (55.0% vs. 30.3% in +6 bp/+6
bp or +6 bp/-6 bp, p = 0.034). There was no difference in
Table 2: Patient characteristics
Characteristics No. of Pts (N = 73) %
Sex
Male 48 65.8
Female 25 34.2
Age, years
median 59
range 24–77
Performance status
ECOG 0–1 60 82.2
ECOG 2 13 17.8
Histopathologic type
Intestinal type 47 64.4
Diffuse type 23 31.5
Unknown 3 4.1
Disease status
Relapsed 19 26.0
Initial stage IV 54 74.0
Metastatic site
Liver 30 41.1
Peritoneum 29 39.7
LN (distant M1 node) 23 31.5
Others 18 24.7
ECOG, eastern cooperative oncology group; LN, lymph node.BMC Cancer 2008, 8:148 http://www.biomedcentral.com/1471-2407/8/148
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RR according to TS enhancer region polymorphism
(47.1% in 3G containing genotype vs. 33.3% in non-3G
containing genotype, p = 0.285). In XPD Arg156Arg, a
higher RR was observed in C/A or A/A genotypes com-
pared with the C/C genotype (52.0% vs. 26.1%, p  =
0.038). The other polymorphisms were not found to be
significantly associated with RR. No association was
observed between polymorphisms and toxicities (data not
shown).
Time to progression, overall survival, and the correlation 
with genotype
Among the polymorphisms investigated, only the 6-bp
deletion homozygote (-6 bp/-6 bp) in TS-3'UTR was
found to be significantly associated with a favorable TTP
and OS. The TTP of patients with -6 bp/-6 bp in TS-3'UTR
was 6.3 months, whereas that of patients with +6 bp/+6
bp or +6 bp/-6 bp was 4.7 months (p = 0.014, p-value
based on log rank test), and a significant difference was
also observed between these genotypes in terms of OS
(17.8 months in -6 bp/-6 bp vs. 10.3 months in +6 bp/+6
bp or +6 bp/-6 bp, p = 0.032, p-value based on log rank
test). In Figure 1 Kaplan-Meier plots are shown and reveal
the relationship between TTP and OS according to the TS-
3'UTR polymorphism. In addition, a prolonged TTP was
observed in the C/A or A/A genotype of XPD Arg156Arg
(6.2 months vs. 4.1 months in C/C, p = 0.022). However,
no association was observed for the other polymorphisms
and TTP or OS (Table 6). Variables showing association
with TTP in univariate analysis with p < 0.10 (6-bp dele-
tion in TS-3'UTR, XPD- Arg156Arg, XPD-Asp312Asn, per-
formance status) were included for multivariate analysis
using Cox proportional hazard regression models. In mul-
tivariate analysis, TS-3'UTR was identified as an independ-
ent prognostic marker of survival (Table 7). The 6-bp
deletion in TS-3'UTR was independently associated with a
prolonged TTP. (Hazard Ratio [HR] = 0.561).
Correlations between in vitro data and the TS 
polymorphism
The above clinical result led to further investigation for
theoretical confirmation in in vitro condition. Using seven
human gastric cancer cell lines and Western blotting, we
investigate for correlations between genotypes, protein
expressions, and 5-FU sensitivities. Two out of seven cell
lines (SNU 601, 620) had -6 bp/-6 bp homozygotes poly-
morphism in TS 3'UTR. Six bp deletion homozygotes
tended to show lower TS protein expression (TS/tubulin
expression ratio 0.88 in -6 bp/-6 bp vs. 1.15 in +6 bp/+6
bp or +6 bp/-6 bp, p = 0.095 by Mann-Whitney U test).
Subsequent Western blot analysis showed lower TS
expression was associated with higher sensitivity to 5-FU
in our in vitro data [36]. Linear regression analysis revealed
a statistically significant correlation between TS protein
expression and the IC50 of 5-FU (p = 0.002, r2 = 0.887),
and the 6-bp deletion polymorphism in TS-3'UTR was
associated with lower TS expression and more sensitivity
to 5-FU in gastric cancer cell lines in vitro.
Discussion
In this work we evaluated the efficacy of modified FOL-
FOX-6 chemotherapy in AGC patients, and examined the
relevance of the relationship between germline genetic
polymorphisms and the clinical outcome. The results
indicate that a modified FOLFOX-6 chemotherapy
appears to be active and well tolerated.
With an overall RR of 43.8%, our results compare favora-
bly with other phase II studies of FOLFOX chemotherapy,
which range from 38% to 56% [3-7]. By contrast to the
FOLFOX-6 regimen for AGC [3], the regimen here omitted
the 5-FU bolus injection in order to reduce myelosuppres-
sion. In terms of toxicities, the modified FOLFOX-6 regi-
men showed an 11.0% occurrence of grade 3 or 4
neutropenia, which is lower than the 38% level shown
with the FOLFOX-6 regimen [3]. Grade 3 or 4 peripheral
sensory neuropathy occurred in only 1.4% of the patients.
This was lower than original FOLFOX-6 using oxaliplatin
of 100 mg/m2 with a median cumulative dose of 901 mg/
m2 for oxaliplatin. In our study the median cumulative
dose of 570 mg/m2 for oxaliplatin which is lower than
original FOLFOX-6. With considering median cumulative
dose of oxaliplatin, this was comparable to other lower
Table 4: Toxicities according to National Cancer Institute 
CTCAE (per patient)
Toxicities Grade 1–2 Grade 3–4
No. of Pts % No. of Pts %
Hematologic
Leucopenia 13 17.8 0 0.0
Neutropenia 10 13.7 8 11.0
Anemia 12 16.4 0 0.0
Thrombocytopenia 5 6.8 1 1.4
Non-hematologic
Neuropathy 12 16.4 1 1.4
AST/ALT abnormality 3 4.1 0 0.0
Nausea 19 26.0 0 0.0
Vomiting 9 12.4 0 0.0
Mucositis 1 1.4 1 1.4
AST, Aspartate aminotransferase; ALT, Alanine aminotransferase.
Table 3: Results of modified FOLFOX-6 chemotherapy
Response No. of Pts (%)
Complete response 0 (0.0)
Partial response 32 (43.8)
Stable disease 21 (28.8)
Progressive disease 20 (27.4)BMC Cancer 2008, 8:148 http://www.biomedcentral.com/1471-2407/8/148
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dose oxaliplatin-based regimen or omitting the 5-FU
bolus [4,7]. In our study, dose modification of oxaliplatin
to 85 mg/m2 was performed if the patient experienced
grade 2 peripheral neuropathy and we strictly followed
the protocol which permitted the initiation of chemother-
apy after recovery from all toxicities less than grade 2.
In the present study, TS and XPD polymorphisms were
found to be associated with RR, and these polymorphisms
could be used as predictive markers. TS, the target of 5-FU,
has been investigated repeatedly in various aspects to pre-
dict the response to 5-FU, in terms of polymorphism,
mRNA and protein expressions [10,16]. In our study, the
6-bp deletion polymorphism in TS-3'UTR was found to be
correlated with favorable clinical outcome. That means
that the patients with -6 bp/-6 bp were found to have a
higher RR and prolonged time to progression. TS-3'UTR
plays a role as a post transcriptional regulator, mainly by
controlling mRNA stability and/or translational effi-
ciency. The 6-bp deletion in TS-3'UTR reduces mRNA sta-
bility and lowers intratumoral TS mRNA levels [18]. A
reduced level of TS mRNA might also lead to a lower TS
protein expression, and make tumors more sensitive to 5-
FU based chemotherapy [13,36,37]. Previous studies in
colorectal cancer provide strong evidence that a lower TS
expression appears to be associated with a higher RR and
prolonged survival with 5-FU based chemotherapy
[11,13,14]. These findings are supported by in vitro data
that -6 bp/-6 bp in TS-3'UTR affect to lower TS expression
and higher sensitivity to 5-FU in gastric cancer cell lines.
In gastric cancer, we confirmed that a 6-bp deletion is
associated with better clinical outcome in homogenous
patients treated with a first line modified FOLFOX-6 regi-
men.
However, some studies conducted in Western countries
[25,26] failed to find a correlation between the 6-bp dele-
tion polymorphism and 5-FU sensitivity in gastric cancer,
while our results are concordant with those of another
Table 5: Response rate according to the clinical factors and the genotypes
Overall frequency Responder
No. of Pts % No. of Pts RR (%) p-value*
Age ≤ 55 31 42.5 15 48.4 0.501
> 55 42 57.5 17 40.5
Performance ECOG 0–1 60 82.2 28 46.7 0.295
ECOG 2 13 17.8 4 30.8
Histotype Intestinal 47 67.1 19 40.4 0.557
Diffuse 23 32.9 11 47.8
unknown 3
Disease status Initial stage IV 54 74.0 27 50.0 0.107
Relapsed 19 26.0 5 26.3
TS in 5'UTR# 2R/2R, 2R/3C, 3C/3C 21 28.8 7 33.3 0.285
2R/3G, 3C/3G, 3G/3G 51 69.9 24 47.1
unknown 1 1.4
TS 6-bp deletion in 3'UTR -6/-6 40 54.8 22 55.0 0.034
+6/+6 or +6/-6 33 45.2 10 30.3
GSTP1-Ile105Val (A105G) A/A 44 60.3 22 50.0 0.191
A/G or G/G 29 39.7 10 34.5
ERCC-Asn118Asn C/C 40 54.8 17 42.5 0.800
C/T or T/T 33 45.2 15 57.5
ERCC-C8092A C/C 44 60.3 18 40.9 0.535
C/A or A/A 29 39.7 14 48.3
XPD- Arg156Arg C/C 23 31.5 6 26.1 0.038
C/A or A/A 50 54.0 26 52.0
XPD-Asp312Asn G/G 8 11.0 1 12.5 0.072
G/A 65 89.0 31 47.7
XPD-Lys751Gln A/A 62 84.9 28 45.2 0.746
A/C or C/C 11 15.1 4 36.4
XRCC1-Arg399Gln G/G 48 65.8 21 43.8 0.984
G/A or A/A 25 34.2 11 44.0
RR, response rate.
*p-value for the comparison between response rate and genotypes, based on Pearson's χ 2 test (using Fisher's exact test, if N ≤ 5).
#Analysis of the TS-5'UTR VNTR polymorphism with G/C SNP change in 3R allele carriers.BMC Cancer 2008, 8:148 http://www.biomedcentral.com/1471-2407/8/148
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study conducted in an Asian [38]. One possible explana-
tion for this contradictory result is ethnic difference.
Caucasian patients had higher proportion of favorable
2R/2R genotype (16.0% to 26.4%) [26,39,40], lower pro-
portion of unfavorable 3R/3R or 3G containing genotypes
in 5'UTR (28.8% to 39.2%) [26,34,40] and lower propor-
tion of favorable -6 bp/-6 bp in 3'UTR (7.8% to 22.0%)
[18,26,34,40]. In contrast, Asian patients showed lower
proportion of favorable 2R/2R (0.0% to 6.0%) [34,41]
higher proportion of unfavorable 3R/3R (66.4% to
72.3%) [34,42] and higher proportion of favorable -6 bp/
Table 6: Comparison of TTP and OS according to the clinical factors and genotypes
Time to progression Overall survival
Median TTP (Mo)* HR# 95% CI p-value# Median OS (Mo)* HR# 95% CI p-value#
Age ≤ 55 5.6 1.000 0.485 11.9 1.000 0.146
> 55 5.0 0.840 0.514–1.371 10.8 1.610 0.847–3.060
Performance ECOG 0–1 6.0 1.000 0.042 12.6 1.000 0.124
ECOG 2 3.7 1.892 1.022–3.501 10.0 1.722 0.862–3.441
Histotype Intestinal 6.1 1.000 0.495 14.5 1.000 0.392
Diffuse 5.6 1.197 0.714–2.009 10.8 1.337 0.687–2.602
Disease status Initial stage IV 5.6 1.000 0.362 12.6 1.000 0.903
Relapsed 6.0 1.288 0.748–2.219 10.8 0.959 0.489–1.881
TS 5'UTR 2R/2R, 2R/3C, 3C/
3C
5.6 1.000 0.781 10.8 1.000 0.244
2R/3G, 3C/3G, 
3G/3G
6.1 0.781 0.415–1.470 17.4 0.669 0.340–1.316
TS 6-bp deletion 
in 3'UTR
+6/+6 or +6/-6 4.7 1.000 0.033 10.3 1.000 0.046
-6/-6 6.3 0.572 0.342–0.956 17.8 0.536 0.291–0.988
GSTP1-Ile105Val A/A 6.0 1.000 0.398 11.9 1.000 0.621
A/G or G/G 6.3 1.243 0.750–2.061 14.5 0.621 0.452–1.606
ERCC-Asn118Asn C/C 6.2 1.000 0.433 14.5 1.000 0.472
C/T or T/T 5.0 0.822 0.503–1.342 11.9 1.251 0.680–2.302
ERCC-C8092A C/C 6.1 1.000 0.826 17.8 1.000 0.326
C/A or A/A 5.6 0.945 0.569–1.568 11.4 1.356 0.739–2.490
XPD- Arg156Arg C/C 4.1 1.000 0.022 10.5 1.000 0.355
C/A or A/A 6.2 0.533 0.311–0.913 14.5 0.738 0.367–1.405
XPD-Asp312Asn G/G 6.1 1.000 0.084 14.0 1.000 0.673
G/A 3.5 1.942 0.914–4.129 10.8 0.800 0.283–2.256
XPD-Lys751Gln A/A 6.1 1.000 0.693 12.6 1.000 0.173
A/C or C/C 4.6 0.872 0.440–1.725 Not reached 0.488 0.174–1.369
XRCC1-
Arg399Gln
G/G 6.1 1.000 0.744 15.3 1.000 0.160
G/A or A/A 5.9 1.090 0.649–1.832 10.3 1.575 0.835–2.971
Mo, months; HR, hazard ratio; CI, confidence interval.
* By Kaplan-Meier analysis
#By Cox proportional hazard regression model, adjusted for performance
Note: If the hazard ratio is greater than 1, the hazard ratio can be thought of as the average increased risk of progression, or death at any point in 
time, compared with the reference group (described above line).
Table 7: Clinical factors and genotypes influencing survival in multivariate analyses
TTP OS
HR (95%CI) p-value HR (95%CI) p-value
TS 6-bp deletion in 3'UTR 0.561 (0.331–0.950) 0.032 0.553 (0.285–1.072) 0.079
XPD-Arg156Arg 0.705 (0.407–1.220) 0.210 0.923 (0.456–1.867) 0.823
XPD-Asp312Asn 1.956 (0.902–4.240) 0.089 0.802 (0.281–2.286) 0.679
Performance (ECOG 0–1 vs. 2) 1.973 (1.034–3.762) 0.073 1.638 (0.816–3.288) 0.165BMC Cancer 2008, 8:148 http://www.biomedcentral.com/1471-2407/8/148
Page 8 of 10
(page number not for citation purposes)
-6 bp (36.4% to 56.0%) [18,34,38]. These differences
between favorable and unfavorable genotype frequencies
might make different results according to ethnic diversity.
The clinical influence of TS polymorphism in 5-FU based
chemotherapy are often controversial because of different
clinical settings (adjuvant vs. palliative), tumor type
(colon  vs. gastric cancer), and different 5-FU infusion
times [16,25,26,39,42-45]. These experimental variables
should be considered when interpreting predictive values
of the TS polymorphism.
Another factor to be taken into consideration is the possi-
ble impact on outcome of other drugs combined with 5-
FU. Even antitumor activity of 5-FU may be decreased by
TS polymorphism, another combined drug might com-
pensate the decreased antitumor activity and make suffi-
cient tumor response. This would make the meaningful
polymorphism in single agent protocol less significant in
combination regimens [46]. Thus this could account for
the differing results with prior reports. A meta-analysis
could perhaps provide some clarity in this area.
XPD (also known as ERCC2) encodes DNA helicase,
which is a member of the nuclear excision repair pathway
and plays a role in repairing platinum-DNA adducts. The
C/C genotype of XPD-Arg156Arg SNP showed lower RR
than C/A or A/A genotype (26.1% vs. 52.0%, p = 0.038)
and shorter TTP (4.1 months vs. 6.2 months, p = 0.022).
The lower RR with a modified FOLFOX-6 chemotherapy
might result from the tendency that the C/C genotype of
XPD- Arg156Arg had a higher DNA repair capacity than C/
A or A/A genotype [32]. However, it did not affect to pro-
longation of survival. The other polymorphisms exam-
ined failed to show any relation with clinical outcome.
In the presented study, we analyzed germline genotype.
Hence the correlation between germline genotype from
peripheral blood and somatic genotype from tumor tis-
sues should be considered. Few studies focused on com-
paring both genotypes. In terms of 28-bp repeat
polymorphism, tumor specific loss of heterozygosity at
the TS locus has been reported [47]. In contrast, some
studies have reported that there is no difference in TS ER
polymorphism between genotypes of tumor and normal
tissues in gastric [41] and colorectal cancer [40].
Herein, we presume that germline genotypes are nearly
identical to somatic genotypes, even though it might not
always reflect the tumor genotype. However, germline
genotypes determined from peripheral blood mononu-
clear cells have many strong points. The germline geno-
types offer the better clinical accessibility and
applicability, compared to tumor tissue DNA or mRNA,
which present difficulties in obtaining and handling sam-
ples. In our results, germline genotypes, which were
obtained by simple blood test, have shown a good associ-
ation with the clinical outcome and are easily interpreted.
In this phase II study, the small sample size (n = 73) might
remains a limitation to clarify the role of polymorphism.
Kaplan-Meier plots of TTP and OS, according to 6-bp deletion polymorphism in 3'UTR of TS Figure 1
Kaplan-Meier plots of TTP and OS, according to 6-bp deletion polymorphism in 3'UTR of TS. The 6-bp deletion 
homozygote (-6 bp/-6 bp) was significantly associated with prolonged TTP (6.3 months vs. 4.7 months in +6 bp/+6 bp or +6 bp/
-6 bp, p = 0.014) and OS (17.8 months vs. 10.3 months in +6 bp/+6 bp or +6 bp/-6 bp, p = 0.032).BMC Cancer 2008, 8:148 http://www.biomedcentral.com/1471-2407/8/148
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However, our patient population was considerably homo-
geneous in terms of ethnicity and chemotherapeutic regi-
men, and this protocol was prospective.
Conclusion
We found that modified FOLFOX-6 chemotherapy
appears to be effective. A 6-bp deletion homozygote of TS-
3'UTR was found to be a predictive marker of the response
and was also found to be associated with a prolonged TTP
in AGC patients on modified FOLFOX-6 chemotherapy.
Moreover, our results suggest that germline genetic poly-
morphisms of TS and XPD may be useful candidates for a
pharmacogenomic prediction of the response to modified
FOLFOX-6 chemotherapy in AGC. Alternative treatment
other than 5-FU or platinum based therapy should be
considered for the patients who have unfavorable geno-
type. We conclude that testing for the TS-3'UTR 6-bp dele-
tion and XPD polymorphisms might be a candidate
pharmacogenomic factors to be explored in the future
larger scale study to identify the gastric cancer patients
who might benefit from 5-FU based first line chemother-
apy.
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